This is a routine 10b5-1 plan sale by an officer, not a new discretionary decision. Traders should not interpret this as negative sentiment, but rather as part of a pre-established exit strategy. Monitor for completion of the sale via Form 4 filings.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $85.40entry
- T+1 · 8mo ago −0.15%α −0.63% · $85.27
- T+5 · 7mo ago −0.41%α −4.03% · $85.05
- T+20 · 7mo ago −5.07%α −14.95% · $81.07
- T+60 · 5mo ago +34.27%α +20.11% · $114.67
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Jeremy Chadwick, an officer of Kymera Therapeutics, filed a Form 144 to report the proposed sale of 14,640 shares, following a series of recent 10b5-1 plan sales totaling over $12.1M in the past month. This filing is part of an ongoing, pre-arranged selling plan and not an isolated event.
Key Facts
- Jeremy Chadwick, an officer of Kymera Therapeutics, filed Form 144 to propose the sale of 14,640 common shares.
- The sale is part of a 10b5-1 trading plan, with recent sales already executed: 7,600 shares (~$649K) on 03/31/2026, 24,727 shares (~$1.98M) on 03/25/2026, 91,250 shares (~$7.06M) on 03/23/2026, and others totaling over $12.1M in the past month.
- The proposed sale proceeds will be received in cash and are not tied to any new insider decision, as 10b5-1 plans are pre-scheduled.
- Recent insider activity shows 4 sell transactions in the last 30 days totaling $3.8M, consistent with this pattern.
Financial Impact
Approximately $1.22M based on 14,640 shares at ~$83.29/share (implied from prior sales), a small fraction of Kymera's $6.8B market cap.
Risk Factors
- Perception risk: Large cumulative insider sales may be viewed negatively by the market despite being pre-planned.
- Execution risk: If future sales under this plan accelerate or expand, it could increase selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003151 |
| Document: 0001950047-26-003151-index.html | 0001950047-26-003151 |
| Document: 0001950047-26-003151.txt | 0001950047-26-003151 |
Track record
37 reports on KYMR
7 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +60.99% at T+60 after the Jun 8, 2026 report. 9 of 14 went positive at some point.
Filters
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $127.09 Now $125.85 −0.98% settles Dec 2
- Oct 29, 202618d ago 8-K Neutral 5/10 No price data
- Oct 29, 202618d ago Press Release Bearish 5/10 Entry $122.60 Now $125.85 −2.65% settles Nov 27
- Oct 28, 202619d ago Press Release Neutral 5/10 Entry $122.60 Now $125.85 +2.65% settles Nov 27
- Oct 27, 202620d ago Institutional Cluster Bullish 4/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $122.51 Now $125.85 +2.73% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $110.85 Now $125.85 +13.53% settles Nov 20
- Aug 5, 202614w ago 8-K Bullish 6/10 Entry $105.48 to $118.63 Now $125.85 +19.31% ▲ +12.47% +13.07% vs SPY
- Jul 7, 202618w ago Insider Cluster Bearish 5/10 Entry $114.16 to $105.48 Now $125.85 −10.24% ▲ +7.60% +10.88% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 5/10 Entry $114.76 to $100.31 Now $125.85 −9.66% ▲ +12.59% +13.44% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers